Vol 105, No 11, March 19, 2002 ISSN 0009-7322 http://circ.ahajournals.org


Crculation. v 105, no. 11 (Mar. 19 2002) **General Collection** V 1 CI743 2)02-03-26 13:49:41



Fighting Heart Disease and Stroke

ulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION







MEDICINE

st page of the Table of Contents

Circulation Electronic Pages
Fetus With Transposition of the Great Arteries *
Mary T. Donofrio, MDe65–e66
Cardiovascular News*
Clinician Update
Oral Anticoagulation for Acute Coronary Syndromes
Marc A. Brouwer, MD; Freek W.A. Verheugt, MD, PhD1270
Brief Rapid Communications
Treatment of Amiodarone-Induced Thyrotoxicosis
Faizel Osman, MB, MRCP, et al1275
Expression of IL-1 Receptor Antagonist by Plasmid DNA
Byung-Kwan Lim, MSc, et al1278
Catheter-Based Endomyocardial Injection With MRI
Robert J. Lederman, MD, et al1282
Clinical Investigation and Reports
Trial of a Distal Embolic Protection Device R
Donald S. Baim, MD, et al1285
Angiogenic Gene Therapy Trial in Patients With Stable Angina
Cindy L. Grines, MD, et al1291
Effect of Azithromycin on Endothelial Function
Nikhil Parchure, MRCP, et al1298
Ventricular Resynchronization
Leslie A. Saxon, MD, et al
Proinsulin and Coronary Heart Disease
Jee-Young Oh, MD, et al1311
Left Ventricular Remodeling, MI, and Heart Failure
Octavio A. Victal, MD, et al1317

OCKET

Δ

RM

Actions of Ba2+ on Human Forearm Blood Flow	
Matthew Dawes, PhD, MRCP, et al	1323
Carotid Sinus Denervation in Humans	
Arthur A.J. Smit, MD, PhD, et al	1329
Prosthetic Heart Valves in Dialysis Patients	
Charles A. Herzog, MD, et al	1336
Risk Stratification in Brugada Syndrome	
Silvia G. Priori, MD, PhD, et al	1342
Renal Effects of Adenosine Antagonist and Furosemide	
Stephen S. Gottlieb, MD, et al	1348
Sympathetic Activity and Survival in ESRD	
Carmine Zoccali, MD, et al	1354
Basic Science Reports	
Fetal Atherogenesis and Aortic Gene Expression 🕅	
Claudio Napoli, MD, et al	1360
Raloxifene Activates P13K/Akt Pathway	
Tommaso Simoncini, MD, PhD, et al	<u>136</u> 8
Propranolol and the Prevention of Heart Failure	
Masahiro Doi, MD, et al	1374
Cariporide and Losartan in Heart Failure	
Jan P. Loennechen, MD, et al	1380
Clinical Cardiology: New Frontiers	
Diastolic Heart Failure	
Michael R. Zile, MD; Dirk L. Brutsaert, MD	1387
Images in Cardiovascular Medicine	
Arrhythmogenic Right Ventricular Cardiomyopathy	
J.A. McCrohon, MD, PhD, et al	1394

Find authenticated court documents without watermarks at docketalarm.com.

Circulation

Circulation Electronic Pages Images in Cardiovascular Medicine Premature Closure of the Foramen Ovale and Ductus Arteriosus in a Fetus With Transposition of the **Great Arteries** Clinician Update **Oral Anticoagulation for Acute Coronary Syndromes** Marc A. Brouwer, MD; Freek W.A. Verheugt, MD, PhD 1270 **Brief Rapid Communications** Successful Treatment of Amiodarone-Induced Thyrotoxicosis Faizel Osman, MB, MRCP; Jayne A. Franklyn, MD, PhD, FRCP; Michael C. Sheppard, PhD, FRCP; Michael D. Gammage, MD, FRCP 1275 Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis Byung-Kwan Lim, MSc; Seong-Choon Choe, MD, PhD; Jae-Ok Shin, BSc; Seong-Hyun Ho, MSc; Jong-Mook Kim, PhD; Seung-Shin Yu, PhD; Sunyoung Kim, PhD; Eun-Seok Jeon, MD, PhD 1278 Catheter-Based Endomyocardial Injection With Real-Time Magnetic Resonance Imaging Robert J. Lederman, MD; Michael A. Guttman, MSc; Dana C. Peters, PhD; Richard B. Thompson, PhD; Jonathan M. Sorger, BS; Alexander J. Dick, MD; Venkatesh K. Raman, MD; Elliot R. McVeigh, PhD 1282 **Clinical Investigation and Reports*** Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts Donald S. Baim, MD; Dennis Wahr, MD; Barry George, MD; Martin B. Leon, MD; Joel Greenberg, MD; Donald E. Cutlip, MD; Unsal Kaya, MS; Jeffrey J. Popma, MD; Kalon K.L. Ho, MD, MSc; Richard E. Kuntz, MD, MSc; on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized

Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina PectorisCindy L. Grines, MD; Matthew W. Watkins, MD; Greg Helmer, MD; William Penny, MD; Jeffrey Brinker, MD;Jonathan D. Marmur, MD; Andrew West, MD; Jeffrey J. Rade, MD; Pran Marrott, MRCP, MSc;H. Kirk Hammond, MD; Robert L. Engler, MDEffect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and

Evidence of Chlamydia pneumoniae Infection Nikhil Parchure, MRCP; Emmanouil G. Zouridakis, MD; Juan Carlos Kaski, MD, DSc, FRCP **1298**

*Supported in concept as prevention of cardiovascular disease by an unrestricted gift from Merck & Co. Pfizer provides an unrestricted gift for subscriptions to *Circulation* for Cardiology Fellows in training.

CIRCULATION (ISSN 0009-7322) is published weekly except combined the first two weeks in January and the last two weeks in December by Lippincott Williams & Wilkins at 16522 Hunters Green Parkway, Hagerstown, MD 21740. Business offices are located at 530 Walnut Street, Philadelphia, PA 19106-3621. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Individuals may subscribe for their personal use at the following rates: \$206 for members of an American Heart Association scientific council and \$275 for nonmembers; international: \$353 for members of an American Heart Association scientific council and \$471 for nonmembers. Periodicals postage paid at Hagerstown, MD and additional mailing offices. POSTMASTER: Send address changes to CIRCULATION, American Heart Association, Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740.

This material was copied at the NLM and may be Subject US Convergent Laws

Find authenticated court documents without watermarks at docketalarm.com.

Effects of Long-Term Biventricular Stimulation for Resynchronization on EchocardiographicMeasures of RemodelingLeslie A. Saxon, MD; Teresa De Marco, MD; Jill Schafer, MS; Kanu Chatterjee, MB; Uday N. Kumar, MD;Elyse Foster, MD; for the VIGOR Congestive Heart Failure Investigators130)4
Sex Differences in the Association Between Proinsulin and Intact Insulin With Coronary Heart Disease in Nondiabetic Older Adults: The Rancho Bernardo Study Jee-Young Oh, MD; Elizabeth Barrett-Connor, MD; Nicole M. Wedick, MS	1
Left Ventricular Volume Reduction by Radiofrequency Heating of Chronic Myocardial Infarction in Patients With Congestive Heart Failure Octavio A. Victal, MD; John R. Teerlink, MD; Efrain Gaxiola, MD; Arthur W. Wallace, MD, PhD; Sergio Najar, MD; David H. Camacho, MD; Augustin Gutierrez, MD; Gabriel Herrera, MD; Gustavo Zuniga, MD; Fausto Mercado-Rios, MD; Mark B. Ratcliffe, MD131	17
Barium Reduces Resting Blood Flow and Inhibits Potassium-Induced Vasodilation in the Human ForearmMatthew Dawes, PhD, MRCP; Christine Sieniawska, BSc, MPhil;Trevor Delves, PhD, CChem, EurClinChem, FRSC; Rahul Dwivedi, MRCP; Philip J. Chowienczyk, FRCP;James M. Ritter, MA, DPhil, FRCP132	23
Long-Term Effects of Carotid Sinus Denervation on Arterial Blood Pressure in Humans Arthur A.J. Smit, MD, PhD; Henri J.L.M. Timmers, MD; Wouter Wieling, MD, PhD; Mariette Wagenaar, MD; Henri A.M. Marres, MD, PhD; Jacques W.M. Lenders, MD, PhD; Gert A. van Montfrans, MD, PhD; John M. Karemaker, PhD	29
Long-Term Survival of Dialysis Patients in the United States With Prosthetic Heart Valves: Should ACC/AHA Practice Guidelines on Valve Selection Be Modified? Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins, MD	36
Natural History of Brugada Syndrome: Insights for Risk Stratification and ManagementSilvia G. Priori, MD, PhD; Carlo Napolitano, MD, PhD; Maurizio Gasparini, MD; Carlo Pappone, MD;Paolo Della Bella, MD; Umberto Giordano, MD; Raffaella Bloise, MD; Carla Giustetto, MD;Roberto De Nardis, MD; Massimiliano Grillo, MD; Elena Ronchetti, PhD; Giovanna Faggiano, MD;Janni Nastoli, BS134	12
BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal FunctionObserved With Diuretic TherapyStephen S. Gottlieb, MD; D. Craig Brater, MD; Ignatius Thomas, MD; Edward Havranek, MD;Robert Bourge, MD; Steven Goldman, MD; Farere Dyer, MD; Miguel Gomez, MD; Donald Bennett, MD;Barry Ticho, MD; Evan Beckman, MD; William T. Abraham, MD134	18
Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal DiseaseCarmine Zoccali, MD; Francesca Mallamaci, MD; Saverio Parlongo, MD; Sebastiano Cutrupi; Francesco Antonio Benedetto, MD; Giovanni Tripepi; Graziella Bonanno, MD; Francesco Rapisarda, MD; Pasquale Fatuzzo, MD; Giuseppe Seminara, MD; Alessandro Cateliotti; Benedetta Stancanelli, MD; Lorenzo Salvatore Malatino, MD135	54

Basic Science Reports

Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDLReceptor-Deficient Mice and Alters Aortic Gene Expression Determined by MicroarrayClaudio Napoli, MD; Filomena de Nigris, PhD; John S. Welch, BS; Federico B. Calara, PhD;Robert O. Stuart, MD; Christopher K. Glass, MD; Wulf Palinski, MD	1360🙂
Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene Tommaso Simoncini, MD, PhD; Andrea R. Genazzani, MD, PhD; James K. Liao, MD	1368
Propranolol Prevents the Development of Heart Failure by Restoring FKBP12.6-Mediated Stabilization of Ryanodine Receptor Masahiro Doi, MD; Masafumi Yano, MD, PhD; Shigeki Kobayashi, MD, PhD; Masateru Kohno, MD; Takahiro Tokuhisa, MD; Shinichi Okuda, MD; Masae Suetsugu, BS; Yuhji Hisamatsu, MD, PhD; Tomoko Ohkusa, MD, PhD; Michihiro Kohno, MD, PhD; Masunori Matsuzaki, MD, PhD	1374

Effects of Cariporide and Losartan on Hypertrophy, Calcium Transients, Contractility, and Gene	
Expression in Congestive Heart Failure	
Jan P. Loennechen, MD; Ulrik Wisløff, MSc, PhD; Geir Falck, MD, PhD; Øyvind Ellingsen, MD, PhD	1380

Clinical Cardiology: New Frontiers

New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I: Diagnosis, Prognosis, and	
Measurements of Diastolic Function	
Michael R. Zile, MD; Dirk L. Brutsaert, MD	1387

Images in Cardiovascular Medicine

Left Ventricular Involvement in Arrhythmogenic Right Ventricular Cardiomyopathy J.A. McCrohon, MD, PhD; A.S. John, MD; C.H. Lorenz, PhD; S.W. Davies, MD; D.J. Pennell, MD 13	94
Annotated Table of Contents A Classified Advertising A	

The cover figure is from the article in this issue by McCrohon et al. Figure 2. T1-weighted turbo spin-echo images before the application of a fat saturation pulse over the region of interest. The arrows point to areas of fatty infiltration of the anterior and inferior myocardium from the epicardial surface. Fatty infiltration is confirmed by the nulling of these areas (black regions) using a fat saturation prepulse in the same plane. The RV free wall shows diffuse high signal consistent with fat (C). See p 1394.

Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts

Donald S. Baim, MD; Dennis Wahr, MD; Barry George, MD; Martin B. Leon, MD; Joel Greenberg, MD; Donald E. Cutlip, MD; Unsal Kaya, MS; Jeffrey J. Popma, MD; Kalon K.L. Ho, MD, MSc; Richard E. Kuntz, MD, MSc; on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators

- Background—Stents provide effective treatment for stenotic saphenous venous aorto-coronary bypass grafts, but their placement carries a 20% incidence of procedure-related complications, which potentially are related to the distal embolization of atherosclerotic debris. We report the first multicenter randomized trial to evaluate use of a distal embolic protection device during stenting of such lesions.
- Methods and Results-Of 801 eligible patients, 406 were randomly assigned to stent placement over the shaft of the distal protection device, and 395 were assigned to stent placement over a conventional 0.014-inch angioplasty guidewire (control group). The primary end point-a composite of death, myocardial infarction, emergency bypass, or target lesion revascularization by 30 days—was observed in 65 patients (16.5%) assigned to the control group and 39 patients (9.6%) assigned to the embolic protection device (P=0.004). This 42% relative reduction in major adverse cardiac events was driven by myocardial infarction (8.6% versus 14.7%, P=0.008) and "no-reflow" phenomenon (3% versus 9%, P=0.02). Clinical benefit was seen even when platelet glycoprotein IIb/IIIa receptor blockers were administered (61% of patients), with composite end points occurring in 10.7% of protection device patients versus 19.4% of control patients (P=0.008).
- Conclusions—Use of this distal protection device during stenting of stenotic venous grafts was associated with a highly significant reduction in major adverse events compared with stenting over a conventional angioplasty guidewire. This demonstrates the importance of distal embolization in causing major adverse cardiac events and the value of embolic protection devices in preventing such complications. (Circulation. 2002;105:1285-1290.)

Key Words: embolism ■ grafting ■ stenosis ■ angioplasty ■ stents

Atheter-based intervention in saphenous venous aorto-Coronary bypass grafts carries a significant (\approx 20%) risk of a major adverse clinical event (MACE) (predominantly myocardial infarction) or reduced antegrade flow (the noreflow phenomenon).1 Several mechanisms have been offered, including spasm of the distal microcirculation, platelet clumping, and most recently, the distal embolization of pieces of friable lipid-rich plaque.² Preliminary work with the PercuSurge GuardWire-a device for transient distal balloon occlusion during angioplasty or stent placement that allows recovery of any liberated plaque by aspiration before restoration of antegrade flow-has demonstrated consistent recovery of plaque constituents (cholesterol crystals, foam cells, fibrous plaque) that otherwise would have embolized into the myocardial bed.3 This initial experience has also suggested a

reduced incidence of myocardial infarction (<6%) compared with the 20% historical rate of infarction seen without such distal protection.⁴ The Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) trial was an 801-patient US multicenter study in which patients undergoing saphenous vein graft intervention were randomized to undergo either stenting with a conventional guidewire or stenting with the GuardWire distal protection device. The SAFER trial was the pivotal trial that led to US Food and Drug Administration approval in August 2001.

Methods

The primary objective of Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) trial was to compare the 30-day clinical outcome after saphenous vein graft stenting plus GuardWire

Correspondence to Donald S. Baim, MD, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail dbaim@partners.org © 2002 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

1285

DOI: 10.1161/01.CIR.0000012783.63093.0C

Find authenticated court documents without watermarks at docketalarm.com.

Received December 28, 2001; revision received January 31, 2002; accepted January 31, 2002.

From the Division of Cardiovascular Diseases, Brigham and Women's Hospital, Boston Mass (D.S.B., J.J.P., R.E.K.); Harvard Clinical Research Institute, Boston, Mass (D.S.B., D.E.C., U.K., K.K.L.H., R.E.K.); Riverside Hospital, Columbus, Ohio (B.G.); St Joseph's Mercy Hospital, Ann Arbor, Mich (D.W.); Cardiovascular Research Foundation, Lenox Hill Hospital, New York, NY (M.B.L.); Florida Hospital, Orlando, Fla (J.G.); and Beth Israel Deaconess Medical Center, Boston, Mass (D.E.C., K.K.L.H.). Dr Leon served as a consultant to PercuSurge Corporation during the trial.

This article originally appeared Online on February 25, 2002 (Circulation. 2002;105:r13-r18).

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.